基于真实世界数据的司库奇尤单抗治疗寻常型银屑病的疗效与安全性分析

Objective To explore the clinical efficacy and safety profile of secukinumab among patients with moderateto-severe plaque psoriasis based on local real-world clinical data. Methods A total of 71 adult patients diagnosed with moderate-to-severe plaque psoriasis and treated at the Shunde Chronic Disease Prevention and Treatment Center from December 2021 to July 2024 were retrospectively included. All participants received standardized subcutaneous injection of 300 mg of secukinumab with a follow-up period of no less than 16 weeks. Dynamic variations in PASI and DLQI scores were adopted to judge therapeutic effects, and all adverse events recorded during follow-up were summarized for safety assessment. Results Dramatic declines in PASI and DLQI scores were observed in all subjects after 16-week intervention(P<0.001). At week 16, the proportions of patients achieving PASI75, PASI90 and PASI100 were 100.00%, 88.73% and 67.61%, separately. The proportion of patients reaching DLQI 0/1(no interference of skin lesions on daily life) reached 83.10% at week 16. None of the participants suspended treatment owing to adverse reactions or unsatisfactory therapeutic effects. Conclusion Secukinumab 300 mg delivers remarkable clinical benefits for patients with moderate-severe plaque psoriasis under routine clinical conditions, with high rates of complete or partial lesion clearance and favorable safety profile. Body mass index(BMI) is an independent factor interfering with the therapeutic response of secukinumab.